Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. See why RXRX stock is a Hold.

Recursion Pharmaceuticals (RXRX) stock gains as the company plans a 20% workforce reduction to streamline operations and extend cash runway to Q4 2027. Read more here.

MIT and Recursion partner for AI drug discovery tool Freely available Boltz-2 algorithm can predict small-molecule binding affinities ...

Before market open, Recursion disclosed in a tersely worded regulatory filing with the Securities and Exchange Commission (SEC) that it was taking a series of measures to streamline its operations.

Factorial Inc. (Factorial), a leader in solid-state battery technology, today announced the launch of Gammatron™, a proprietary AI-driven simulation platform designed to accelerate the ...

Recursion, Exscientia, and AI drug discovery’s moment of truth Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger.

Discover real-time Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead ...

Recursion Pharmaceuticals will lay off roughly 20% of its workforce, affecting some 160 employees, in a bid to extend its cash runway. In an SEC filing on Tuesday, the Utah-based biotech announced ...